Global Human Immumoglobulin (PH4) for Intravenous Injection Market Growth 2026-2032
The global Human Immumoglobulin (PH4) for Intravenous Injection market size is predicted to grow from US$ 12237 million in 2025 to US$ 21756 million in 2032; it is expected to grow at a CAGR of 8.6% from 2026 to 2032.
In 2025, global Human Immumoglobulin (PH4) for Intravenous Injection production reached approximately 150.3 tons, with an average global market price of around 83.2 USD/g.
Human Immunoglobulin (PH4) for Intravenous Injection is a sterile blood product derived from pooled plasma of healthy donors, with a pH value maintained at 3.8-4.4 to ensure biological activity. It contains over 95% IgG antibodies, undergoes virus inactivation and removal processes, and serves dual roles of immune replacement and immune regulation. Clinically, it is mainly indicated for primary immunoglobulin deficiencies (e.g., X-linked agammaglobulinemia), secondary deficiencies (e.g., severe infections, neonatal sepsis), and autoimmune diseases (e.g., idiopathic thrombocytopenic purpura, Kawasaki disease). It is a prescription-only biological product requiring strict quality control and regulatory approval.
Driven by aging populations, rising prevalence of autoimmune diseases, expanded clinical indications, and post-pandemic emphasis on immunotherapy, global demand for Human Immunoglobulin (PH4) for Intravenous Injection remains robust, often facing supply shortages due to plasma source constraints. Business opportunities lie in optimizing plasma collection networks to boost raw material supply, advancing production technologies (e.g., nanofiltration, low-pH incubation) for improved yield and safety, developing high-concentration or specialty formulations to meet personalized treatment needs, exploring emerging markets with growing healthcare access, and leveraging policy support for biopharmaceuticals to expand market penetration and enhance product accessibility through pricing and reimbursement strategies.
LP Information, Inc. (LPI) ' newest research report, the ?Human Immumoglobulin (PH4) for Intravenous Injection Industry Forecast? looks at past sales and reviews total world Human Immumoglobulin (PH4) for Intravenous Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Human Immumoglobulin (PH4) for Intravenous Injection sales for 2026 through 2032. With Human Immumoglobulin (PH4) for Intravenous Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Immumoglobulin (PH4) for Intravenous Injection industry.
This Insight Report provides a comprehensive analysis of the global Human Immumoglobulin (PH4) for Intravenous Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Immumoglobulin (PH4) for Intravenous Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Human Immumoglobulin (PH4) for Intravenous Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Immumoglobulin (PH4) for Intravenous Injection and breaks down the forecast by Concentration, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Immumoglobulin (PH4) for Intravenous Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Immumoglobulin (PH4) for Intravenous Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Concentration:
In 2025, global Human Immumoglobulin (PH4) for Intravenous Injection production reached approximately 150.3 tons, with an average global market price of around 83.2 USD/g.
Human Immunoglobulin (PH4) for Intravenous Injection is a sterile blood product derived from pooled plasma of healthy donors, with a pH value maintained at 3.8-4.4 to ensure biological activity. It contains over 95% IgG antibodies, undergoes virus inactivation and removal processes, and serves dual roles of immune replacement and immune regulation. Clinically, it is mainly indicated for primary immunoglobulin deficiencies (e.g., X-linked agammaglobulinemia), secondary deficiencies (e.g., severe infections, neonatal sepsis), and autoimmune diseases (e.g., idiopathic thrombocytopenic purpura, Kawasaki disease). It is a prescription-only biological product requiring strict quality control and regulatory approval.
Driven by aging populations, rising prevalence of autoimmune diseases, expanded clinical indications, and post-pandemic emphasis on immunotherapy, global demand for Human Immunoglobulin (PH4) for Intravenous Injection remains robust, often facing supply shortages due to plasma source constraints. Business opportunities lie in optimizing plasma collection networks to boost raw material supply, advancing production technologies (e.g., nanofiltration, low-pH incubation) for improved yield and safety, developing high-concentration or specialty formulations to meet personalized treatment needs, exploring emerging markets with growing healthcare access, and leveraging policy support for biopharmaceuticals to expand market penetration and enhance product accessibility through pricing and reimbursement strategies.
LP Information, Inc. (LPI) ' newest research report, the ?Human Immumoglobulin (PH4) for Intravenous Injection Industry Forecast? looks at past sales and reviews total world Human Immumoglobulin (PH4) for Intravenous Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Human Immumoglobulin (PH4) for Intravenous Injection sales for 2026 through 2032. With Human Immumoglobulin (PH4) for Intravenous Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Immumoglobulin (PH4) for Intravenous Injection industry.
This Insight Report provides a comprehensive analysis of the global Human Immumoglobulin (PH4) for Intravenous Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Immumoglobulin (PH4) for Intravenous Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Human Immumoglobulin (PH4) for Intravenous Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Immumoglobulin (PH4) for Intravenous Injection and breaks down the forecast by Concentration, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Immumoglobulin (PH4) for Intravenous Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Immumoglobulin (PH4) for Intravenous Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Concentration:
- 5%
- 10%
- 20%
- Standard-Qualified Plasma
- High-Safety Plasma
- Special-Indication
- Cohn-Fractionation
- Chromatography-Purified
- Ultrafiltration-Refined
- Immunodeficiency Disease
- Autoimmune Disease
- Severe Infectious Disease
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Boya-Bio
- Beijing Tiantan Biological Products
- Guangdong Shuagnlin Bio-pharmacy
- Weiguang Biological
- Hualan Bio
- CTBB
- Sinopharm
- Nanyue Biopharming
- Shanghai RAAS
- ADMA Biologics
- Grand Shuyang
- PAFC
- Weiguang Biological Products
- Beijing Bohui Innovation Biotechnology
- CSL Behring
- Takeda
- Grifols
- Octapharma
- Bio Products Laboratory
- Kedrion
- LFB
- GC Biopharma
- What is the 10-year outlook for the global Human Immumoglobulin (PH4) for Intravenous Injection market?
- What factors are driving Human Immumoglobulin (PH4) for Intravenous Injection market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How doHuman Immumoglobulin (PH4) for Intravenous Injection market opportunities vary by end market size?
- How does Human Immumoglobulin (PH4) for Intravenous Injection break out by Concentration, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Human Immumoglobulin (PH4) for Intravenous Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Human Immumoglobulin (PH4) for Intravenous Injection by Country/Region, 2021, 2025 & 2032
2.2 Human Immumoglobulin (PH4) for Intravenous Injection Segment by Concentration
2.2.1 5%
2.2.2 10%
2.2.3 20%
2.2.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration
2.2.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
2.2.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Concentration (2021-2026)
2.2.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Concentration (2021-2026)
2.3 Human Immumoglobulin (PH4) for Intravenous Injection Segment by Source Plasma Screening Standard
2.3.1 Standard-Qualified Plasma
2.3.2 High-Safety Plasma
2.3.3 Special-Indication
2.3.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales by Source Plasma Screening Standard
2.3.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Source Plasma Screening Standard (2021-2026)
2.3.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Source Plasma Screening Standard (2021-2026)
2.3.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Source Plasma Screening Standard (2021-2026)
2.4 Human Immumoglobulin (PH4) for Intravenous Injection Segment by Production Process
2.4.1 Cohn-Fractionation
2.4.2 Chromatography-Purified
2.4.3 Ultrafiltration-Refined
2.4.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales by Production Process
2.4.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Production Process (2021-2026)
2.4.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Production Process (2021-2026)
2.4.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Production Process (2021-2026)
2.5 Human Immumoglobulin (PH4) for Intravenous Injection Segment by Application
2.5.1 Immunodeficiency Disease
2.5.2 Autoimmune Disease
2.5.3 Severe Infectious Disease
2.5.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application
2.5.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2021-2026)
2.5.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Breakdown Data by Company
3.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales by Company (2021-2026)
3.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Company (2021-2026)
3.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Company (2021-2026)
3.2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company (2021-2026)
3.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Company
3.4 Key Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Product Location Distribution
3.4.2 Players Human Immumoglobulin (PH4) for Intravenous Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth
4.4 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth
4.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth
4.6 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth
5 AMERICAS
5.1 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country
5.1.1 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
5.1.2 Americas Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026)
5.2 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026)
5.3 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region
6.1.1 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2026)
6.1.2 APAC Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2021-2026)
6.2 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026)
6.3 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection by Country
7.1.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
7.1.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026)
7.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026)
7.3 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection by Country
8.1.1 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026)
8.3 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
10.3 Manufacturing Process Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
10.4 Industry Chain Structure of Human Immumoglobulin (PH4) for Intravenous Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Immumoglobulin (PH4) for Intravenous Injection Distributors
11.3 Human Immumoglobulin (PH4) for Intravenous Injection Customer
12 WORLD FORECAST REVIEW FOR HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION BY GEOGRAPHIC REGION
12.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size Forecast by Region
12.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecast by Region (2027-2032)
12.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecast by Concentration (2027-2032)
12.7 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Boya-Bio
13.1.1 Boya-Bio Company Information
13.1.2 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Boya-Bio Main Business Overview
13.1.5 Boya-Bio Latest Developments
13.2 Beijing Tiantan Biological Products
13.2.1 Beijing Tiantan Biological Products Company Information
13.2.2 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Beijing Tiantan Biological Products Main Business Overview
13.2.5 Beijing Tiantan Biological Products Latest Developments
13.3 Guangdong Shuagnlin Bio-pharmacy
13.3.1 Guangdong Shuagnlin Bio-pharmacy Company Information
13.3.2 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Guangdong Shuagnlin Bio-pharmacy Main Business Overview
13.3.5 Guangdong Shuagnlin Bio-pharmacy Latest Developments
13.4 Weiguang Biological
13.4.1 Weiguang Biological Company Information
13.4.2 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Weiguang Biological Main Business Overview
13.4.5 Weiguang Biological Latest Developments
13.5 Hualan Bio
13.5.1 Hualan Bio Company Information
13.5.2 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Hualan Bio Main Business Overview
13.5.5 Hualan Bio Latest Developments
13.6 CTBB
13.6.1 CTBB Company Information
13.6.2 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CTBB Main Business Overview
13.6.5 CTBB Latest Developments
13.7 Sinopharm
13.7.1 Sinopharm Company Information
13.7.2 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.7.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sinopharm Main Business Overview
13.7.5 Sinopharm Latest Developments
13.8 Nanyue Biopharming
13.8.1 Nanyue Biopharming Company Information
13.8.2 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nanyue Biopharming Main Business Overview
13.8.5 Nanyue Biopharming Latest Developments
13.9 Shanghai RAAS
13.9.1 Shanghai RAAS Company Information
13.9.2 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Shanghai RAAS Main Business Overview
13.9.5 Shanghai RAAS Latest Developments
13.10 ADMA Biologics
13.10.1 ADMA Biologics Company Information
13.10.2 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.10.3 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 ADMA Biologics Main Business Overview
13.10.5 ADMA Biologics Latest Developments
13.11 Grand Shuyang
13.11.1 Grand Shuyang Company Information
13.11.2 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.11.3 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Grand Shuyang Main Business Overview
13.11.5 Grand Shuyang Latest Developments
13.12 PAFC
13.12.1 PAFC Company Information
13.12.2 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.12.3 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 PAFC Main Business Overview
13.12.5 PAFC Latest Developments
13.13 Weiguang Biological Products
13.13.1 Weiguang Biological Products Company Information
13.13.2 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.13.3 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Weiguang Biological Products Main Business Overview
13.13.5 Weiguang Biological Products Latest Developments
13.14 Beijing Bohui Innovation Biotechnology
13.14.1 Beijing Bohui Innovation Biotechnology Company Information
13.14.2 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.14.3 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Beijing Bohui Innovation Biotechnology Main Business Overview
13.14.5 Beijing Bohui Innovation Biotechnology Latest Developments
13.15 CSL Behring
13.15.1 CSL Behring Company Information
13.15.2 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.15.3 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 CSL Behring Main Business Overview
13.15.5 CSL Behring Latest Developments
13.16 Takeda
13.16.1 Takeda Company Information
13.16.2 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.16.3 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Takeda Main Business Overview
13.16.5 Takeda Latest Developments
13.17 Grifols
13.17.1 Grifols Company Information
13.17.2 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.17.3 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Grifols Main Business Overview
13.17.5 Grifols Latest Developments
13.18 Octapharma
13.18.1 Octapharma Company Information
13.18.2 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.18.3 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Octapharma Main Business Overview
13.18.5 Octapharma Latest Developments
13.19 Bio Products Laboratory
13.19.1 Bio Products Laboratory Company Information
13.19.2 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.19.3 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Bio Products Laboratory Main Business Overview
13.19.5 Bio Products Laboratory Latest Developments
13.20 Kedrion
13.20.1 Kedrion Company Information
13.20.2 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.20.3 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Kedrion Main Business Overview
13.20.5 Kedrion Latest Developments
13.21 LFB
13.21.1 LFB Company Information
13.21.2 LFB Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.21.3 LFB Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 LFB Main Business Overview
13.21.5 LFB Latest Developments
13.22 GC Biopharma
13.22.1 GC Biopharma Company Information
13.22.2 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.22.3 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 GC Biopharma Main Business Overview
13.22.5 GC Biopharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Human Immumoglobulin (PH4) for Intravenous Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Human Immumoglobulin (PH4) for Intravenous Injection by Country/Region, 2021, 2025 & 2032
2.2 Human Immumoglobulin (PH4) for Intravenous Injection Segment by Concentration
2.2.1 5%
2.2.2 10%
2.2.3 20%
2.2.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration
2.2.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
2.2.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Concentration (2021-2026)
2.2.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Concentration (2021-2026)
2.3 Human Immumoglobulin (PH4) for Intravenous Injection Segment by Source Plasma Screening Standard
2.3.1 Standard-Qualified Plasma
2.3.2 High-Safety Plasma
2.3.3 Special-Indication
2.3.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales by Source Plasma Screening Standard
2.3.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Source Plasma Screening Standard (2021-2026)
2.3.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Source Plasma Screening Standard (2021-2026)
2.3.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Source Plasma Screening Standard (2021-2026)
2.4 Human Immumoglobulin (PH4) for Intravenous Injection Segment by Production Process
2.4.1 Cohn-Fractionation
2.4.2 Chromatography-Purified
2.4.3 Ultrafiltration-Refined
2.4.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales by Production Process
2.4.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Production Process (2021-2026)
2.4.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Production Process (2021-2026)
2.4.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Production Process (2021-2026)
2.5 Human Immumoglobulin (PH4) for Intravenous Injection Segment by Application
2.5.1 Immunodeficiency Disease
2.5.2 Autoimmune Disease
2.5.3 Severe Infectious Disease
2.5.4 Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application
2.5.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2021-2026)
2.5.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Breakdown Data by Company
3.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales by Company (2021-2026)
3.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Company (2021-2026)
3.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Company (2021-2026)
3.2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company (2021-2026)
3.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Company
3.4 Key Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Product Location Distribution
3.4.2 Players Human Immumoglobulin (PH4) for Intravenous Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth
4.4 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth
4.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth
4.6 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth
5 AMERICAS
5.1 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country
5.1.1 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
5.1.2 Americas Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026)
5.2 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026)
5.3 Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region
6.1.1 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2026)
6.1.2 APAC Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2021-2026)
6.2 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026)
6.3 APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection by Country
7.1.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
7.1.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026)
7.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026)
7.3 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection by Country
8.1.1 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026)
8.3 Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
10.3 Manufacturing Process Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
10.4 Industry Chain Structure of Human Immumoglobulin (PH4) for Intravenous Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Immumoglobulin (PH4) for Intravenous Injection Distributors
11.3 Human Immumoglobulin (PH4) for Intravenous Injection Customer
12 WORLD FORECAST REVIEW FOR HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION BY GEOGRAPHIC REGION
12.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size Forecast by Region
12.1.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecast by Region (2027-2032)
12.1.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecast by Concentration (2027-2032)
12.7 Global Human Immumoglobulin (PH4) for Intravenous Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Boya-Bio
13.1.1 Boya-Bio Company Information
13.1.2 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Boya-Bio Main Business Overview
13.1.5 Boya-Bio Latest Developments
13.2 Beijing Tiantan Biological Products
13.2.1 Beijing Tiantan Biological Products Company Information
13.2.2 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Beijing Tiantan Biological Products Main Business Overview
13.2.5 Beijing Tiantan Biological Products Latest Developments
13.3 Guangdong Shuagnlin Bio-pharmacy
13.3.1 Guangdong Shuagnlin Bio-pharmacy Company Information
13.3.2 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Guangdong Shuagnlin Bio-pharmacy Main Business Overview
13.3.5 Guangdong Shuagnlin Bio-pharmacy Latest Developments
13.4 Weiguang Biological
13.4.1 Weiguang Biological Company Information
13.4.2 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Weiguang Biological Main Business Overview
13.4.5 Weiguang Biological Latest Developments
13.5 Hualan Bio
13.5.1 Hualan Bio Company Information
13.5.2 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Hualan Bio Main Business Overview
13.5.5 Hualan Bio Latest Developments
13.6 CTBB
13.6.1 CTBB Company Information
13.6.2 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 CTBB Main Business Overview
13.6.5 CTBB Latest Developments
13.7 Sinopharm
13.7.1 Sinopharm Company Information
13.7.2 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.7.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sinopharm Main Business Overview
13.7.5 Sinopharm Latest Developments
13.8 Nanyue Biopharming
13.8.1 Nanyue Biopharming Company Information
13.8.2 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nanyue Biopharming Main Business Overview
13.8.5 Nanyue Biopharming Latest Developments
13.9 Shanghai RAAS
13.9.1 Shanghai RAAS Company Information
13.9.2 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Shanghai RAAS Main Business Overview
13.9.5 Shanghai RAAS Latest Developments
13.10 ADMA Biologics
13.10.1 ADMA Biologics Company Information
13.10.2 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.10.3 ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 ADMA Biologics Main Business Overview
13.10.5 ADMA Biologics Latest Developments
13.11 Grand Shuyang
13.11.1 Grand Shuyang Company Information
13.11.2 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.11.3 Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Grand Shuyang Main Business Overview
13.11.5 Grand Shuyang Latest Developments
13.12 PAFC
13.12.1 PAFC Company Information
13.12.2 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.12.3 PAFC Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 PAFC Main Business Overview
13.12.5 PAFC Latest Developments
13.13 Weiguang Biological Products
13.13.1 Weiguang Biological Products Company Information
13.13.2 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.13.3 Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Weiguang Biological Products Main Business Overview
13.13.5 Weiguang Biological Products Latest Developments
13.14 Beijing Bohui Innovation Biotechnology
13.14.1 Beijing Bohui Innovation Biotechnology Company Information
13.14.2 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.14.3 Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Beijing Bohui Innovation Biotechnology Main Business Overview
13.14.5 Beijing Bohui Innovation Biotechnology Latest Developments
13.15 CSL Behring
13.15.1 CSL Behring Company Information
13.15.2 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.15.3 CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 CSL Behring Main Business Overview
13.15.5 CSL Behring Latest Developments
13.16 Takeda
13.16.1 Takeda Company Information
13.16.2 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.16.3 Takeda Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Takeda Main Business Overview
13.16.5 Takeda Latest Developments
13.17 Grifols
13.17.1 Grifols Company Information
13.17.2 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.17.3 Grifols Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Grifols Main Business Overview
13.17.5 Grifols Latest Developments
13.18 Octapharma
13.18.1 Octapharma Company Information
13.18.2 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.18.3 Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Octapharma Main Business Overview
13.18.5 Octapharma Latest Developments
13.19 Bio Products Laboratory
13.19.1 Bio Products Laboratory Company Information
13.19.2 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.19.3 Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Bio Products Laboratory Main Business Overview
13.19.5 Bio Products Laboratory Latest Developments
13.20 Kedrion
13.20.1 Kedrion Company Information
13.20.2 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.20.3 Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Kedrion Main Business Overview
13.20.5 Kedrion Latest Developments
13.21 LFB
13.21.1 LFB Company Information
13.21.2 LFB Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.21.3 LFB Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 LFB Main Business Overview
13.21.5 LFB Latest Developments
13.22 GC Biopharma
13.22.1 GC Biopharma Company Information
13.22.2 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.22.3 GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 GC Biopharma Main Business Overview
13.22.5 GC Biopharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 5%
Table 4. Major Players of 10%
Table 5. Major Players of 20%
Table 6. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 7. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Table 8. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Concentration (2021-2026) & ($ million)
Table 9. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Concentration (2021-2026)
Table 10. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Concentration (2021-2026) & (US$/g)
Table 11. Major Players of Standard-Qualified Plasma
Table 12. Major Players of High-Safety Plasma
Table 13. Major Players of Special-Indication
Table 14. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Source Plasma Screening Standard (2021-2026) & (Tons)
Table 15. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Source Plasma Screening Standard (2021-2026)
Table 16. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Source Plasma Screening Standard (2021-2026) & ($ million)
Table 17. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Source Plasma Screening Standard (2021-2026)
Table 18. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Source Plasma Screening Standard (2021-2026) & (US$/g)
Table 19. Major Players of Cohn-Fractionation
Table 20. Major Players of Chromatography-Purified
Table 21. Major Players of Ultrafiltration-Refined
Table 22. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Production Process (2021-2026) & (Tons)
Table 23. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Production Process (2021-2026)
Table 24. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Production Process (2021-2026) & ($ million)
Table 25. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Production Process (2021-2026)
Table 26. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Production Process (2021-2026) & (US$/g)
Table 27. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale by Application (2021-2026) & (Tons)
Table 28. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2021-2026)
Table 29. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2021-2026) & ($ million)
Table 30. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2021-2026)
Table 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Application (2021-2026) & (US$/g)
Table 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Company (2021-2026) & (Tons)
Table 33. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Company (2021-2026)
Table 34. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company (2021-2026)
Table 36. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Company (2021-2026) & (US$/g)
Table 37. Key Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Producing Area Distribution and Sales Area
Table 38. Players Human Immumoglobulin (PH4) for Intravenous Injection Products Offered
Table 39. Human Immumoglobulin (PH4) for Intravenous Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Geographic Region (2021-2026) & (Tons)
Table 43. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share Geographic Region (2021-2026)
Table 44. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country/Region (2021-2026) & (Tons)
Table 47. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2021-2026)
Table 48. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (Tons)
Table 51. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026)
Table 52. Americas Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 54. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (Tons)
Table 55. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2026) & (Tons)
Table 56. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2021-2026)
Table 57. APAC Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 59. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (Tons)
Table 60. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (Tons)
Table 61. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 63. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (Tons)
Table 64. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (Tons)
Table 65. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 67. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (Tons)
Table 68. Key Market Drivers & Growth Opportunities of Human Immumoglobulin (PH4) for Intravenous Injection
Table 69. Key Market Challenges & Risks of Human Immumoglobulin (PH4) for Intravenous Injection
Table 70. Key Industry Trends of Human Immumoglobulin (PH4) for Intravenous Injection
Table 71. Human Immumoglobulin (PH4) for Intravenous Injection Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Human Immumoglobulin (PH4) for Intravenous Injection Distributors List
Table 74. Human Immumoglobulin (PH4) for Intravenous Injection Customer List
Table 75. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Region (2027-2032) & (Tons)
Table 76. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (Tons)
Table 78. Americas Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Region (2027-2032) & (Tons)
Table 80. APAC Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (Tons)
Table 82. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (Tons)
Table 84. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Concentration (2027-2032) & (Tons)
Table 86. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Concentration (2027-2032) & ($ millions)
Table 87. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Application (2027-2032) & (Tons)
Table 88. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Boya-Bio Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 90. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 91. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 92. Boya-Bio Main Business
Table 93. Boya-Bio Latest Developments
Table 94. Beijing Tiantan Biological Products Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 95. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 96. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 97. Beijing Tiantan Biological Products Main Business
Table 98. Beijing Tiantan Biological Products Latest Developments
Table 99. Guangdong Shuagnlin Bio-pharmacy Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 100. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 101. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 102. Guangdong Shuagnlin Bio-pharmacy Main Business
Table 103. Guangdong Shuagnlin Bio-pharmacy Latest Developments
Table 104. Weiguang Biological Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 105. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 106. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 107. Weiguang Biological Main Business
Table 108. Weiguang Biological Latest Developments
Table 109. Hualan Bio Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 110. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 111. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 112. Hualan Bio Main Business
Table 113. Hualan Bio Latest Developments
Table 114. CTBB Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 115. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 116. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 117. CTBB Main Business
Table 118. CTBB Latest Developments
Table 119. Sinopharm Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 120. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 121. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 122. Sinopharm Main Business
Table 123. Sinopharm Latest Developments
Table 124. Nanyue Biopharming Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 125. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 126. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 127. Nanyue Biopharming Main Business
Table 128. Nanyue Biopharming Latest Developments
Table 129. Shanghai RAAS Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 130. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 131. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 132. Shanghai RAAS Main Business
Table 133. Shanghai RAAS Latest Developments
Table 134. ADMA Biologics Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 135. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 136. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 137. ADMA Biologics Main Business
Table 138. ADMA Biologics Latest Developments
Table 139. Grand Shuyang Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 140. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 141. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 142. Grand Shuyang Main Business
Table 143. Grand Shuyang Latest Developments
Table 144. PAFC Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 145. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 146. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 147. PAFC Main Business
Table 148. PAFC Latest Developments
Table 149. Weiguang Biological Products Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 150. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 151. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 152. Weiguang Biological Products Main Business
Table 153. Weiguang Biological Products Latest Developments
Table 154. Beijing Bohui Innovation Biotechnology Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 155. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 156. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 157. Beijing Bohui Innovation Biotechnology Main Business
Table 158. Beijing Bohui Innovation Biotechnology Latest Developments
Table 159. CSL Behring Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 160. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 161. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 162. CSL Behring Main Business
Table 163. CSL Behring Latest Developments
Table 164. Takeda Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 165. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 166. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 167. Takeda Main Business
Table 168. Takeda Latest Developments
Table 169. Grifols Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 170. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 171. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 172. Grifols Main Business
Table 173. Grifols Latest Developments
Table 174. Octapharma Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 175. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 176. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 177. Octapharma Main Business
Table 178. Octapharma Latest Developments
Table 179. Bio Products Laboratory Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 180. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 181. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 182. Bio Products Laboratory Main Business
Table 183. Bio Products Laboratory Latest Developments
Table 184. Kedrion Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 185. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 186. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 187. Kedrion Main Business
Table 188. Kedrion Latest Developments
Table 189. LFB Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 190. LFB Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 191. LFB Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 192. LFB Main Business
Table 193. LFB Latest Developments
Table 194. GC Biopharma Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 195. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 196. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 197. GC Biopharma Main Business
Table 198. GC Biopharma Latest Developments
Table 1. Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Human Immumoglobulin (PH4) for Intravenous Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 5%
Table 4. Major Players of 10%
Table 5. Major Players of 20%
Table 6. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 7. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Table 8. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Concentration (2021-2026) & ($ million)
Table 9. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Concentration (2021-2026)
Table 10. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Concentration (2021-2026) & (US$/g)
Table 11. Major Players of Standard-Qualified Plasma
Table 12. Major Players of High-Safety Plasma
Table 13. Major Players of Special-Indication
Table 14. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Source Plasma Screening Standard (2021-2026) & (Tons)
Table 15. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Source Plasma Screening Standard (2021-2026)
Table 16. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Source Plasma Screening Standard (2021-2026) & ($ million)
Table 17. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Source Plasma Screening Standard (2021-2026)
Table 18. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Source Plasma Screening Standard (2021-2026) & (US$/g)
Table 19. Major Players of Cohn-Fractionation
Table 20. Major Players of Chromatography-Purified
Table 21. Major Players of Ultrafiltration-Refined
Table 22. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Production Process (2021-2026) & (Tons)
Table 23. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Production Process (2021-2026)
Table 24. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Production Process (2021-2026) & ($ million)
Table 25. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Production Process (2021-2026)
Table 26. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Production Process (2021-2026) & (US$/g)
Table 27. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale by Application (2021-2026) & (Tons)
Table 28. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2021-2026)
Table 29. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Application (2021-2026) & ($ million)
Table 30. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2021-2026)
Table 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Application (2021-2026) & (US$/g)
Table 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Company (2021-2026) & (Tons)
Table 33. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Company (2021-2026)
Table 34. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company (2021-2026)
Table 36. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Price by Company (2021-2026) & (US$/g)
Table 37. Key Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Producing Area Distribution and Sales Area
Table 38. Players Human Immumoglobulin (PH4) for Intravenous Injection Products Offered
Table 39. Human Immumoglobulin (PH4) for Intravenous Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Geographic Region (2021-2026) & (Tons)
Table 43. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share Geographic Region (2021-2026)
Table 44. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country/Region (2021-2026) & (Tons)
Table 47. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2021-2026)
Table 48. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (Tons)
Table 51. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026)
Table 52. Americas Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 54. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (Tons)
Table 55. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2021-2026) & (Tons)
Table 56. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2021-2026)
Table 57. APAC Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 59. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (Tons)
Table 60. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (Tons)
Table 61. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 63. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (Tons)
Table 64. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2021-2026) & (Tons)
Table 65. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Concentration (2021-2026) & (Tons)
Table 67. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Application (2021-2026) & (Tons)
Table 68. Key Market Drivers & Growth Opportunities of Human Immumoglobulin (PH4) for Intravenous Injection
Table 69. Key Market Challenges & Risks of Human Immumoglobulin (PH4) for Intravenous Injection
Table 70. Key Industry Trends of Human Immumoglobulin (PH4) for Intravenous Injection
Table 71. Human Immumoglobulin (PH4) for Intravenous Injection Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Human Immumoglobulin (PH4) for Intravenous Injection Distributors List
Table 74. Human Immumoglobulin (PH4) for Intravenous Injection Customer List
Table 75. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Region (2027-2032) & (Tons)
Table 76. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (Tons)
Table 78. Americas Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Region (2027-2032) & (Tons)
Table 80. APAC Human Immumoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (Tons)
Table 82. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2027-2032) & (Tons)
Table 84. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Concentration (2027-2032) & (Tons)
Table 86. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Concentration (2027-2032) & ($ millions)
Table 87. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Forecast by Application (2027-2032) & (Tons)
Table 88. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Boya-Bio Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 90. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 91. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 92. Boya-Bio Main Business
Table 93. Boya-Bio Latest Developments
Table 94. Beijing Tiantan Biological Products Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 95. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 96. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 97. Beijing Tiantan Biological Products Main Business
Table 98. Beijing Tiantan Biological Products Latest Developments
Table 99. Guangdong Shuagnlin Bio-pharmacy Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 100. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 101. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 102. Guangdong Shuagnlin Bio-pharmacy Main Business
Table 103. Guangdong Shuagnlin Bio-pharmacy Latest Developments
Table 104. Weiguang Biological Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 105. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 106. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 107. Weiguang Biological Main Business
Table 108. Weiguang Biological Latest Developments
Table 109. Hualan Bio Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 110. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 111. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 112. Hualan Bio Main Business
Table 113. Hualan Bio Latest Developments
Table 114. CTBB Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 115. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 116. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 117. CTBB Main Business
Table 118. CTBB Latest Developments
Table 119. Sinopharm Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 120. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 121. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 122. Sinopharm Main Business
Table 123. Sinopharm Latest Developments
Table 124. Nanyue Biopharming Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 125. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 126. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 127. Nanyue Biopharming Main Business
Table 128. Nanyue Biopharming Latest Developments
Table 129. Shanghai RAAS Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 130. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 131. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 132. Shanghai RAAS Main Business
Table 133. Shanghai RAAS Latest Developments
Table 134. ADMA Biologics Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 135. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 136. ADMA Biologics Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 137. ADMA Biologics Main Business
Table 138. ADMA Biologics Latest Developments
Table 139. Grand Shuyang Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 140. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 141. Grand Shuyang Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 142. Grand Shuyang Main Business
Table 143. Grand Shuyang Latest Developments
Table 144. PAFC Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 145. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 146. PAFC Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 147. PAFC Main Business
Table 148. PAFC Latest Developments
Table 149. Weiguang Biological Products Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 150. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 151. Weiguang Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 152. Weiguang Biological Products Main Business
Table 153. Weiguang Biological Products Latest Developments
Table 154. Beijing Bohui Innovation Biotechnology Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 155. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 156. Beijing Bohui Innovation Biotechnology Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 157. Beijing Bohui Innovation Biotechnology Main Business
Table 158. Beijing Bohui Innovation Biotechnology Latest Developments
Table 159. CSL Behring Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 160. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 161. CSL Behring Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 162. CSL Behring Main Business
Table 163. CSL Behring Latest Developments
Table 164. Takeda Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 165. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 166. Takeda Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 167. Takeda Main Business
Table 168. Takeda Latest Developments
Table 169. Grifols Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 170. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 171. Grifols Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 172. Grifols Main Business
Table 173. Grifols Latest Developments
Table 174. Octapharma Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 175. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 176. Octapharma Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 177. Octapharma Main Business
Table 178. Octapharma Latest Developments
Table 179. Bio Products Laboratory Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 180. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 181. Bio Products Laboratory Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 182. Bio Products Laboratory Main Business
Table 183. Bio Products Laboratory Latest Developments
Table 184. Kedrion Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 185. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 186. Kedrion Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 187. Kedrion Main Business
Table 188. Kedrion Latest Developments
Table 189. LFB Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 190. LFB Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 191. LFB Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 192. LFB Main Business
Table 193. LFB Latest Developments
Table 194. GC Biopharma Basic Information, Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors
Table 195. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
Table 196. GC Biopharma Human Immumoglobulin (PH4) for Intravenous Injection Sales (Tons), Revenue ($ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 197. GC Biopharma Main Business
Table 198. GC Biopharma Latest Developments
LIST OF FIGURES
Figure 1. Picture of Human Immumoglobulin (PH4) for Intravenous Injection
Figure 2. Human Immumoglobulin (PH4) for Intravenous Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate 2021-2032 (Tons)
Figure 7. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Human Immumoglobulin (PH4) for Intravenous Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2025)
Figure 10. Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 5%
Figure 12. Product Picture of 10%
Figure 13. Product Picture of 20%
Figure 14. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration in 2026
Figure 15. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Concentration (2021-2026)
Figure 16. Product Picture of Standard-Qualified Plasma
Figure 17. Product Picture of High-Safety Plasma
Figure 18. Product Picture of Special-Indication
Figure 19. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Source Plasma Screening Standard in 2026
Figure 20. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Source Plasma Screening Standard (2021-2026)
Figure 21. Product Picture of Cohn-Fractionation
Figure 22. Product Picture of Chromatography-Purified
Figure 23. Product Picture of Ultrafiltration-Refined
Figure 24. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Production Process in 2026
Figure 25. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Production Process (2021-2026)
Figure 26. Human Immumoglobulin (PH4) for Intravenous Injection Consumed in Immunodeficiency Disease
Figure 27. Global Human Immumoglobulin (PH4) for Intravenous Injection Market: Immunodeficiency Disease (2021-2026) & (Tons)
Figure 28. Human Immumoglobulin (PH4) for Intravenous Injection Consumed in Autoimmune Disease
Figure 29. Global Human Immumoglobulin (PH4) for Intravenous Injection Market: Autoimmune Disease (2021-2026) & (Tons)
Figure 30. Human Immumoglobulin (PH4) for Intravenous Injection Consumed in Severe Infectious Disease
Figure 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Market: Severe Infectious Disease (2021-2026) & (Tons)
Figure 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2025)
Figure 33. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application in 2026
Figure 34. Human Immumoglobulin (PH4) for Intravenous Injection Sales by Company in 2026 (Tons)
Figure 35. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Company in 2026
Figure 36. Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Company in 2026 ($ millions)
Figure 37. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company in 2026
Figure 38. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Geographic Region in 2026
Figure 40. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales 2021-2026 (Tons)
Figure 41. Americas Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2021-2026 ($ millions)
Figure 42. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales 2021-2026 (Tons)
Figure 43. APAC Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2021-2026 ($ millions)
Figure 44. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales 2021-2026 (Tons)
Figure 45. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales 2021-2026 (Tons)
Figure 47. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2021-2026 ($ millions)
Figure 48. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2026
Figure 49. Americas Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2021-2026)
Figure 50. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Figure 51. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026)
Figure 52. United States Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region in 2026
Figure 57. APAC Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2021-2026)
Figure 58. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Figure 59. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026)
Figure 60. China Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 64. India Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2026
Figure 68. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2021-2026)
Figure 69. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Figure 70. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026)
Figure 71. Germany Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 72. France Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Figure 78. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026)
Figure 79. Egypt Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Human Immumoglobulin (PH4) for Intravenous Injection in 2026
Figure 85. Manufacturing Process Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
Figure 86. Industry Chain Structure of Human Immumoglobulin (PH4) for Intravenous Injection
Figure 87. Channels of Distribution
Figure 88. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Forecast by Region (2027-2032)
Figure 89. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Concentration (2027-2032)
Figure 91. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Concentration (2027-2032)
Figure 92. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Human Immumoglobulin (PH4) for Intravenous Injection
Figure 2. Human Immumoglobulin (PH4) for Intravenous Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate 2021-2032 (Tons)
Figure 7. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Human Immumoglobulin (PH4) for Intravenous Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2025)
Figure 10. Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 5%
Figure 12. Product Picture of 10%
Figure 13. Product Picture of 20%
Figure 14. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration in 2026
Figure 15. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Concentration (2021-2026)
Figure 16. Product Picture of Standard-Qualified Plasma
Figure 17. Product Picture of High-Safety Plasma
Figure 18. Product Picture of Special-Indication
Figure 19. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Source Plasma Screening Standard in 2026
Figure 20. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Source Plasma Screening Standard (2021-2026)
Figure 21. Product Picture of Cohn-Fractionation
Figure 22. Product Picture of Chromatography-Purified
Figure 23. Product Picture of Ultrafiltration-Refined
Figure 24. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Production Process in 2026
Figure 25. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Production Process (2021-2026)
Figure 26. Human Immumoglobulin (PH4) for Intravenous Injection Consumed in Immunodeficiency Disease
Figure 27. Global Human Immumoglobulin (PH4) for Intravenous Injection Market: Immunodeficiency Disease (2021-2026) & (Tons)
Figure 28. Human Immumoglobulin (PH4) for Intravenous Injection Consumed in Autoimmune Disease
Figure 29. Global Human Immumoglobulin (PH4) for Intravenous Injection Market: Autoimmune Disease (2021-2026) & (Tons)
Figure 30. Human Immumoglobulin (PH4) for Intravenous Injection Consumed in Severe Infectious Disease
Figure 31. Global Human Immumoglobulin (PH4) for Intravenous Injection Market: Severe Infectious Disease (2021-2026) & (Tons)
Figure 32. Global Human Immumoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2025)
Figure 33. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application in 2026
Figure 34. Human Immumoglobulin (PH4) for Intravenous Injection Sales by Company in 2026 (Tons)
Figure 35. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Company in 2026
Figure 36. Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Company in 2026 ($ millions)
Figure 37. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company in 2026
Figure 38. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Geographic Region in 2026
Figure 40. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales 2021-2026 (Tons)
Figure 41. Americas Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2021-2026 ($ millions)
Figure 42. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales 2021-2026 (Tons)
Figure 43. APAC Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2021-2026 ($ millions)
Figure 44. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales 2021-2026 (Tons)
Figure 45. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales 2021-2026 (Tons)
Figure 47. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2021-2026 ($ millions)
Figure 48. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2026
Figure 49. Americas Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2021-2026)
Figure 50. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Figure 51. Americas Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026)
Figure 52. United States Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region in 2026
Figure 57. APAC Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2021-2026)
Figure 58. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Figure 59. APAC Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026)
Figure 60. China Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 64. India Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2026
Figure 68. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2021-2026)
Figure 69. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Figure 70. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026)
Figure 71. Germany Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 72. France Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Concentration (2021-2026)
Figure 78. Middle East & Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2021-2026)
Figure 79. Egypt Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Human Immumoglobulin (PH4) for Intravenous Injection in 2026
Figure 85. Manufacturing Process Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
Figure 86. Industry Chain Structure of Human Immumoglobulin (PH4) for Intravenous Injection
Figure 87. Channels of Distribution
Figure 88. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Forecast by Region (2027-2032)
Figure 89. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Concentration (2027-2032)
Figure 91. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Concentration (2027-2032)
Figure 92. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Application (2027-2032)
